ASH 2023 | The addition of lenalidomide to MEC chemotherapy to improve outcomes of patients with R/R AML
Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discusses the findings of a Phase II study (NCT03118466) which aimed to investigate the efficacy of a salvage chemotherapy regimen of mitoxantrone, etoposide, and cytarabine (MEC) when combined with lenalidomide in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). This combination was found to produce greater responses and improved overall survival (OS) in patients than historical controls treated with MEC chemotherapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Acceleron, Agios, Celgene/BMS, Keros Therapeutics, Novartis, Taiho, Takeda, Gilead
Research Funding: Agios, AstraZeneca, Celgene/BMS, GSK, Janssen, Novartis
